Neurological toxicity during metastatic melanoma treatment with fotemustine.
暂无分享,去创建一个
[1] Kevin B. Kim,et al. Pilot study of high‐dose, concurrent biochemotherapy for advanced melanoma , 2004, Cancer.
[2] M. Weichenthal,et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] W. Stolz,et al. Severe neurological disabilities after complete remission of advanced malignant melanoma following fotemustine therapy in combination with total brain irradiation. , 2002, Melanoma research.
[4] E. Alba,et al. Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: a pilot study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] T. Petit,et al. Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients , 1995, Melanoma research.
[6] M. Namer,et al. Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases , 1990, Cancer.